Loading...

FEMY FEMASYS INC Capital Structure Changes 8-K Filing

FMSY

FMY

FEMASYS INC

(FEMY)

2026 8-K

Management Change

Financial Results Update

Warrant Amendments

Nasdaq Compliance Extension

Stock Offering Announcement

FDA Clearance Secured

Financial Results Update

Partner Order Announcement

Funding Agreement Details

FDA Approval Secured

Delisting Update

Management Change

Stock Offering Details

Regulatory Approval

Geographic Expansion

Non-Compliance with Listing...

Equity Offerings

Market Expansion

New Product Launches

Equity Offerings

Forced Delisting

Financial Statements

Financial Results

Distribution Partnerships

Product Approval

Date Correction

Financial Results

Corporate Presentation

Distribution Partnerships

Investor Presentation

Product Approval

Financial Results Announcement

Annual Meeting of Stockholders

Other Special Situation

Financial Results Announcement

Regulation FD Disclosure

Financial Results Announcement

Regulation FD Disclosure, O...

Completion of Enrollment in...

Appointment of Director

Private Placement

Financial Results Announcement

Compliance Regained

Regulation FD Disclosure, O...

Financial Results and Manag...

Other Special Situation

Patent Application

Regulation FD Disclosure, O...

Annual Meeting of Stockholders

Management Changes

Financial Results and Corpo...

Product Approval in Canada

Securities Purchase Agreement

Product Approval in Canada

Regulation FD Disclosure

Financial Results and Bylaw...

External Links:

Femasys Inc. amended its outstanding Securities Purchase Agreement on March 19, 2026, allowing lenders to receive Series D-1 Warrants, with a total of 16,378,563 warrants issued at an exercise price of $0.58. Additionally, Joshua Silverman resigned as a director on March 17, 2026, and Kenneth D. Eichenbaum was appointed as his replacement effective March 18, 2026.

AI Assistant

FEMASYS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.